Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00730769|
Recruitment Status : Completed
First Posted : August 8, 2008
Last Update Posted : September 21, 2011
The objectives of this study were:
- To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment.
- To compare the exposure to ganciclovir, at steady state, after oral valganciclovir with respect to ganciclovir given intravenously (i.v.).
- Evaluate the security of this treatment with valganciclovir.
|Condition or disease||Intervention/treatment||Phase|
|Cytomegalovirus Infection||Drug: Single arm (ganciclovir and valganciclovir)||Phase 4|
SOT recipients (kidney, liver and heart transplant) presenting CMV infection or disease were eligible for inclusion if they were ≥18 years of age and presented a positive CMV antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells (PBMC). Patients excluded were those with severe CMV tissue invasive disease, unable to receive oral medication, absolute neutrophil counts less than 500/ mm3, platelets <25000 platelets/mm3, Hemoglobin< 80g/l or estimated glomerular filtration rate< 10 mL/min (according to the Cockcroft-Gault formula).
Patients received a short induction treatment with ganciclovir i.v (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at the dose of 5 mg/kg/12h, by a peripherical vein infusion of one hour, during 5 days followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg/12h during 16 days, after meals, until complete a total of 21 days of treatment. In patients with impaired renal function ganciclovir i.v. and oral valganciclovir doses were adjusted at each visit according to estimated Glomerular Filtration Rate (GFR) by Cockcroft-Gault equation, as recommended by the manufacturer.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients.|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||July 2007|
|Actual Study Completion Date :||July 2008|
Experimental: Single arm
Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
Drug: Single arm (ganciclovir and valganciclovir)
Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
- Dissapeareance of CMV (pp65) antigenemia, determined in peripheral blood mononuclear cells (PBMC). [ Time Frame: Baseline, day 5, 10, 15, 21 of treatment and day 30, 60 and 90 of follow-up. ]
- Dissapareance of Cytomegalovirus viremia measured by PCR, determined in plasma samples. [ Time Frame: Basal, day 5, 10, 15 and 21 of treatment and 30, 60 and 90 of treatment. ]
- Area under the curve (AUC) of Ganciclovir after ganciclovir i.v. and valganciclovir oral in steady state. [ Time Frame: Day 5 (ganciclovir i.v) and day 15 (valganciclovir oral) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00730769
|Hospital Universitari Bellvitge- Transplant Departments (Liver, Heart and Kidney)|
|L'Hospitalet de Llobregat, Barcelone, Spain, 08907|
|Study Chair:||Salvador - Gil-Vernet, Medicine||Nephrology Department. Hospital Universitari of Bellvitge|